

Edgar Filing: Gabelli Healthcare & WellnessRx Trust - Form N-CSRS

Gabelli Healthcare & WellnessRx Trust
Form N-CSRS
September 05, 2008

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM N-CSR

CERTIFIED SHAREHOLDER REPORT OF REGISTERED MANAGEMENT INVESTMENT COMPANIES

Investment Company Act file number 811-22021

The Gabelli Healthcare & Wellness(Rx) Trust
(Exact name of registrant as specified in charter)

One Corporate Center
Rye, New York 10580-1422
(Address of principal executive offices) (Zip code)

Agnes Mullady
Gabelli Funds, LLC
One Corporate Center
Rye, New York 10580-1422
(Name and address of agent for service)

registrant's telephone number, including area code: 1-800-422-3554

Date of fiscal year end: December 31

Date of reporting period: June 30, 2008

Form N-CSR is to be used by management investment companies to file reports with the Commission not later than 10 days after the transmission to stockholders of any report that is required to be transmitted to stockholders under Rule 30e-1 under the Investment Company Act of 1940 (17 CFR 270.30e-1). The Commission may use the information provided on Form N-CSR in its regulatory, disclosure review, inspection, and policymaking roles.

A registrant is required to disclose the information specified by Form N-CSR, and the Commission will make this information public. A registrant is not required to respond to the collection of information contained in Form N-CSR unless the Form displays a currently valid Office of Management and Budget ("OMB") control number. Please direct comments concerning the accuracy of the information collection burden estimate and any suggestions for reducing the burden to Secretary, Securities and Exchange Commission, 100 F Street, NE, Washington, DC 20549. The OMB has reviewed this collection of information under the clearance requirements of 44 U.S.C. ss. 3507.

ITEM 1. REPORTS TO STOCKHOLDERS.

The Report to Shareholders is attached herewith.

Edgar Filing: Gabelli Healthcare & WellnessRx Trust - Form N-CSRS

THE [LOGO]
HEALTHCARE &
WELLNESS (RX) TRUST

THE GABELLI HEALTHCARE & WELLNESS (RX) TRUST

Semi-Annual Report
June 30, 2008

TO OUR SHAREHOLDERS,

The Gabelli Healthcare & Wellness (Rx) Trust's (the "Fund") net asset value ("NAV") total return declined 9.96% during the first half of 2008, compared with losses of 11.90% and 13.29% for the Standard & Poor's ("S&P") 500 Index and the Dow Jones Industrial Average, respectively. The total return for the Fund's publicly traded shares was (12.41)% during the first half of the year. On June 30, 2008, the Fund's NAV per share was \$7.23, while the price of the publicly traded shares closed at \$6.21 on the New York Stock Exchange ("NYSE").

COMPARATIVE RESULTS

AVERAGE ANNUAL RETURNS THROUGH JUNE 30, 2008 (a)

	Quarter -----	Year to Date -----	Since Inception (06/28/07) -----
GABELLI HEALTHCARE & WELLNESS (RX) TRUST			
NAV TOTAL RETURN (b).....	(4.74)%	(9.96)%	(9.06)%
INVESTMENT TOTAL RETURN (c).....	(6.76)	(12.41)	(21.83)
S&P 500 Index.....	(2.72)	(11.90)	(13.19) (d)
S&P 500 Health Care Index.....	(1.24)	(12.61)	(12.03)
S&P 500 Consumer Staples Index.....	(5.34)	(7.43)	0.67

- (a) RETURNS REPRESENT PAST PERFORMANCE AND DO NOT GUARANTEE FUTURE RESULTS. Investment returns and the principal value of an investment will fluctuate. When shares are sold, they may be worth more or less than their original cost. Current performance may be lower or higher than the performance data presented. Visit www.gabelli.com for performance information as of the most recent month end. Performance returns for periods less than one year are not annualized. INVESTORS SHOULD CAREFULLY CONSIDER THE INVESTMENT OBJECTIVES, RISKS, CHARGES, AND EXPENSES OF THE FUND BEFORE INVESTING. The S&P 500, S&P 500 Health Care, and S&P 500 Consumer Staples Indices are unmanaged indicators of stock market performance. Dividends are considered reinvested. You cannot invest directly in an index.
- (b) Total returns and average annual returns reflect changes in the NAV per share and reinvestment of distributions at NAV on the ex-dividend date and are net of expenses. Since inception return is based on an initial NAV of \$8.00.
- (c) Total returns and average annual returns reflect changes in closing market values on the New York Stock Exchange and reinvestment of distributions. Since inception return is based on an initial offering price of \$8.00.
- (d) From June 30, 2007, the date closest to the Fund's inception for which

Edgar Filing: Gabelli Healthcare & WellnessRx Trust - Form N-CSRS

data is available.

We have separated the portfolio managers' commentary from the financial statements and investment portfolios due to corporate governance regulations stipulated by the Sarbanes-Oxley Act of 2002. We have done this to ensure that the content of the portfolio managers' commentary is unrestricted. The financial statements and investment portfolios are mailed separately from the commentary. Both the commentary and the financial statements, including the portfolios of investments, will be available on our website at www.gabelli.com/funds.

THE GABELLI HEALTHCARE & WELLNESS (RX) TRUST SUMMARY OF PORTFOLIO HOLDINGS (UNAUDITED)

The following table presents portfolio holdings as a percent of total investments as of June 30, 2008:

Food.....	27.9%
U.S. Treasury Bills.....	14.9%
Health Care Equipment and Supplies.....	12.8%
Health Care Providers and Services.....	9.8%
Food and Staples Retailing.....	9.7%
Pharmaceuticals.....	7.0%
Biotechnology.....	6.5%
Beverages.....	5.6%
Commercial Services and Supplies.....	2.5%
Insurance.....	1.1%
Computers and Peripheral.....	1.0%
Chemicals.....	0.7%
Aerospace and Defense.....	0.5%

	100.0%
	=====

The Fund files a complete schedule of portfolio holdings with the Securities and Exchange Commission (the "SEC") for the first and third quarters of each fiscal year on Form N-Q, the last of which was filed for the quarter ended March 31, 2008. Shareholders may obtain this information at www.gabelli.com or by calling the Fund at 800-GABELLI (800-422-3554). The Fund's Form N-Q is available on the SEC's website at www.sec.gov and may also be reviewed and copied at the SEC's Public Reference Room in Washington, DC. Information on the operation of the Public Reference Room may be obtained by calling 1-800-SEC-0330.

PROXY VOTING

The Fund files Form N-PX with its complete proxy voting record for the 12 months ended June 30th, no later than August 31st of each year. A description of the Fund's proxy voting policies, procedures, and how the Fund voted proxies relating to portfolio securities is available without charge, upon request, by (i) calling 800-GABELLI (800-422-3554); (ii) writing to The Gabelli Funds at One Corporate Center, Rye, NY 10580-1422; or (iii) visiting the SEC's website at www.sec.gov.

SHAREHOLDER MEETING - MAY 19, 2008 - FINAL RESULTS

The Gabelli Healthcare & Wellness (Rx) Trust's Annual Meeting of Shareholders was held on May 19, 2008 at the Greenwich Library in Greenwich,

Edgar Filing: Gabelli Healthcare & WellnessRx Trust - Form N-CSRS

Connecticut. At that meeting, shareholders elected Mario J. Gabelli, Vincent D. Enright, and Anthonie C. van Ekris as Trustees of the Fund. A total of 7,390,444 votes, 7,425,457 votes, and 7,416,683 votes were cast in favor of each Trustee and a total of 183,925 votes, 148,912 votes, and 157,686 votes were withheld for each Trustee, respectively.

Thomas E. Bratter, Anthony J. Colavita, James P. Conn, Robert C. Kolodny, and Salvatore J. Zizza continue to serve in their capacities as Trustees of the Fund.

We thank you for your participation and appreciate your continued support.

2

THE GABELLI HEALTHCARE & WELLNESS (RX) TRUST SCHEDULE OF INVESTMENTS JUNE 30, 2008 (UNAUDITED)

SHARES		COST	MARKET VALUE
	COMMON STOCKS--85.0%		
	AEROSPACE AND DEFENSE--0.5%		
4,000	DRS Technologies Inc.	\$ 315,035	\$ 314,880
	BEVERAGES--5.6%		
45,000	Dr. Pepper Snapple Group Inc.+	1,162,935	944,100
10,000	Hansen Natural Corp.+	428,307	288,200
65,000	ITO EN Ltd.	1,436,333	1,023,497
7,500	ITO EN Ltd., Preference	172,236	79,813
10,000	PepsiCo Inc.	671,995	635,900
3,000	Sapporo Holdings Ltd.	18,226	20,992
10,000	The Coca-Cola Co.	533,701	519,800
		4,423,733	3,512,302
	BIOTECHNOLOGY--6.5%		
25,000	3SBio Inc., ADR+	311,280	226,500
200	Alnylam Pharmaceuticals Inc.+	3,216	5,346
200	Arena Pharmaceuticals Inc.+	2,222	1,038
40,000	Array Biopharma Inc.+	456,689	188,000
8,000	Cephalon Inc.+	562,578	533,520
6,500	Crucell NV, ADR+	98,245	103,870
60,000	CytRx Corp.+	119,472	39,000
5,000	Gilead Sciences Inc.+	197,211	264,750
20,000	Monogram Biosciences Inc.+	32,650	22,000
4,000	Myriad Genetics Inc.+	167,679	182,080
7,500	Omrix Biopharmaceuticals Inc.+	96,056	118,050
2,993	RXi Pharmaceuticals Corp.+	44,835	23,944
130,000	Tercica Inc.+	1,144,450	1,147,900
100,000	Third Wave Technologies Inc.+	1,114,150	1,116,000
20,000	Vanda Pharmaceuticals Inc.+	314,078	65,800
		4,664,811	4,037,798
	CHEMICALS--0.7%		
12,000	International Flavors & Fragrances		

Edgar Filing: Gabelli Healthcare & WellnessRx Trust - Form N-CSRS

	Inc.	571,938	468,720
		-----	-----
	COMMERCIAL SERVICES AND SUPPLIES--2.5%		
25,000	ChoicePoint Inc.+	1,204,816	1,205,000
10,000	Weight Watchers International Inc.	392,595	356,100
		-----	-----
		1,597,411	1,561,100
		-----	-----
	COMPUTERS AND PERIPHERAL--1.0%		
3,000	Diebold Inc.	113,836	106,740
20,000	Electronic Data Systems Corp.	489,351	492,800
		-----	-----
		603,187	599,540
		-----	-----
	FOOD--27.9%		
12,800	Cadbury plc, ADR	693,535	644,096
40,000	Campbell Soup Co.	1,437,303	1,338,400
75,000	Dean Foods Co.+	1,902,590	1,471,500
50,000	Del Monte Foods Co.	503,345	355,000
22,000	Flowers Foods Inc.	463,990	623,480
20,000	General Mills Inc.	1,136,982	1,215,400
20,000	Groupe Danone	1,542,303	1,404,415
2,000	Groupe Danone, ADR	32,442	28,108
12,000	H.J. Heinz Co.	533,871	574,200
30,000	Hain Celestial Group Inc.+	869,430	704,400
15,000	Kellogg Co.	766,007	720,300
16,000	Kerry Group plc, Cl. A	419,845	475,605
47,000	Kikkoman Corp.	612,500	574,083
52,600	Lifeway Foods Inc.+	572,634	625,414
100,000	Meiji Seika Kaisha Ltd.	491,785	426,614
15,000	Morinaga Milk Industry Co. Ltd.	48,287	38,988
39,000	Nestle SA	1,571,277	1,762,263
200	Nestle SA, ADR	19,094	22,658
6,000	Parmalat SpA	22,155	15,682
5,000	Rock Field Co. Ltd.	71,047	65,876
55,000	Smart Balance Inc.+	455,662	396,550
15,000	The J.M. Smucker Co.	757,913	609,600
7,300	Wimm-Bill-Dann Foods OJSC, ADR	719,377	768,106
17,000	Wm. Wrigley Jr. Co.	1,311,730	1,322,260
40,000	YAKULT HONSHA Co. Ltd.	963,651	1,126,336
		-----	-----
		17,918,755	17,309,334
		-----	-----
	FOOD AND STAPLES RETAILING--9.7%		
6,000	Costco Wholesale Corp.	347,483	420,840
33,000	CVS Caremark Corp.	1,201,195	1,305,810
12,000	SUPERVALU Inc.	399,638	370,680
35,777	The Great Atlantic & Pacific Tea Co. Inc.+	1,064,994	816,431
500	Village Super Market Inc., Cl. A	23,378	19,290
10,000	Wal-Mart Stores Inc.	458,576	562,000
24,000	Walgreen Co.	923,755	780,240
74,000	Whole Foods Market Inc.	2,762,227	1,753,060
		-----	-----
		7,181,246	6,028,351
		-----	-----
	HEALTH CARE EQUIPMENT AND SUPPLIES--12.7%		
13,000	Advanced Medical Optics Inc.+	357,774	243,620
7,500	Align Technology Inc.+	88,408	78,675
175,000	AMDL Inc.+ (a) (b) (c)	391,522	507,500
40,000	AngioDynamics Inc.+	729,281	544,800

Edgar Filing: Gabelli Healthcare & WellnessRx Trust - Form N-CSRS

16,000	Boston Scientific Corp.+	219,820	196,640
10,000	Covidien Ltd.	414,948	478,900

See accompanying notes to financial statements.

3

THE GABELLI HEALTHCARE & WELLNESS (RX) TRUST
 SCHEDULE OF INVESTMENTS (CONTINUED)
 JUNE 30, 2008 (UNAUDITED)

SHARES -----		COST -----	MARKET VALUE -----
COMMON STOCKS (CONTINUED)			
HEALTH CARE EQUIPMENT AND SUPPLIES (CONTINUED)			
31,000	Cutera Inc.+	\$ 498,381	\$ 279,930
21,200	ev3 Inc.+	347,405	200,976
27,000	Greatbatch Inc.+	677,232	467,100
12,000	Inverness Medical Innovations Inc.+	368,342	398,040
14,000	Kinetic Concepts Inc.+	796,765	558,740
15,000	Medical Action Industries Inc.+	270,907	155,550
9,000	Medtronic Inc.	470,816	465,750
4,200	Mentor Corp.	142,779	116,844
30,400	Micrus Endovascular Corp.+	667,234	426,208
9,000	Orthofix International NV+	326,370	260,550
20,000	St. Jude Medical Inc.+	833,593	817,600
30,000	Thoratec Corp.+	560,717	521,700
85,000	Vascular Solutions Inc.+	782,390	552,500
9,000	Zimmer Holdings Inc.+	735,874	612,450
		-----	-----
		9,680,558	7,884,073
		-----	-----
HEALTH CARE PROVIDERS AND SERVICES--9.8%			
14,000	Aetna Inc.	703,453	567,420
5,000	Amedisys Inc.+	187,700	252,100
20,000	American Dental Partners Inc.+	183,516	237,400
7,000	AmerisourceBergen Corp.	314,391	279,930
5,000	Apria Healthcare Group Inc.+	99,858	96,950
8,000	Cardinal Health Inc.	469,607	412,640
3,000	Chemed Corp.	126,720	109,830
126,000	Continucare Corp.+	266,642	296,100
14,000	Healthways Inc.+	442,693	414,400
45,000	HLTH Corp.+	615,954	509,400
12,000	IMS Health Inc.	324,226	279,600
165,000	MEDecision Inc.+	1,088,547	1,097,250
20,000	Omnicare Inc.	670,713	524,400
1,000	Owens & Minor Inc.	35,498	45,690
15,000	PSS World Medical Inc.+	253,010	244,500
28,200	UnitedHealth Group Inc.	1,305,511	740,250
		-----	-----
		7,088,039	6,107,860
		-----	-----
INSURANCE--1.1%			
10,000	SAFECO Corp.	668,323	671,600

Edgar Filing: Gabelli Healthcare & WellnessRx Trust - Form N-CSRS

- + Non-income producing security.
- ++ Represents annualized yield at date of purchase.
- ADR American Depositary Receipt

GEOGRAPHIC DIVERSIFICATION	% OF MARKET VALUE	MARKET VALUE
North America	84.6%	\$ 52,570,158
Europe	8.4	5,224,803
Japan	5.4	3,356,199
Latin America	1.6	965,950
Total Investments	100.0%	\$ 62,117,110
	=====	=====

See accompanying notes to financial statements.

4

THE GABELLI HEALTHCARE & WELLNESS (RX) TRUST

STATEMENT OF ASSETS AND LIABILITIES JUNE 30, 2008 (UNAUDITED)

ASSETS:	
Investments, at value (cost \$68,895,158)	\$ 62,117,110
Foreign currency, at value (cost \$896)	914
Receivable for investments sold	119,306
Dividends and interest receivable	43,895
Prepaid expense	1,368
TOTAL ASSETS	62,282,593
LIABILITIES:	
Payable to custodian	154,320
Payable for investments purchased	715,451
Payable for investment advisory fees	52,174
Payable for payroll expenses	23,744
Payable for accounting fees	3,750
Other accrued expenses	51,219
TOTAL LIABILITIES	1,000,658
NET ASSETS applicable to 8,474,459 shares outstanding	\$ 61,281,935
NET ASSETS CONSIST OF:	
Paid-in capital, at \$0.001 par value	\$ 67,795,672
Accumulated net investment loss	(92,112)
Accumulated net realized gain on investments and foreign currency transactions	357,074
Net unrealized depreciation on investments	(6,778,048)

Edgar Filing: Gabelli Healthcare & WellnessRx Trust - Form N-CSRS

Net unrealized depreciation on foreign currency translations	(651)

NET ASSETS	\$ 61,281,935
	=====
NET ASSET VALUE PER COMMON SHARE:	
(\$61,281,935 / 8,474,459 shares outstanding:	
unlimited number of shares authorized)	\$ 7.23
	=====

STATEMENT OF OPERATIONS FOR THE SIX MONTHS ENDED JUNE 30, 2008 (UNAUDITED)

INVESTMENT INCOME:	
Dividends (net of foreign taxes of \$6,046)	\$ 348,959
Interest	144,201

TOTAL INVESTMENT INCOME	493,160

EXPENSES:	
Investment advisory fees	321,385
Shareholder communications expenses	197,932
Payroll expenses	35,897
Trustees' fees	29,030
Shareholder services fees	28,197
Legal and audit fees	25,442
Accounting fees	22,500
Custodian fees	3,325
Miscellaneous expenses	19,969

TOTAL EXPENSES	683,677
Less: Custodian fee credits	(1,939)

NET EXPENSES	681,738

NET INVESTMENT LOSS	(188,578)

NET REALIZED AND UNREALIZED GAIN (LOSS) ON INVESTMENTS AND FOREIGN CURRENCY:	
Net realized gain on investments	39,260
Net realized loss on foreign currency transactions	(532)

Net realized gain on investments and foreign currency transactions	38,728

Net change in unrealized appreciation/depreciation: on investments	(6,636,655)
on foreign currency translations	(819)

Net change in unrealized appreciation/depreciation on investments and foreign currency translations	(6,637,474)

NET REALIZED AND UNREALIZED GAIN (LOSS) ON INVESTMENTS AND FOREIGN CURRENCY	(6,598,746)

NET DECREASE IN NET ASSETS RESULTING FROM OPERATIONS	\$ (6,787,324)

=====

See accompanying notes to financial statements.

5

THE GABELLI HEALTHCARE & WELLNESS (RX) TRUST
STATEMENT OF CHANGES IN NET ASSETS

	SIX MONTHS ENDED JUNE 30, 2008 (UNAUDITED)

OPERATIONS:	
Net investment income (loss)	\$ (188,578)
Net realized gain on investments and foreign currency transactions	38,728
Net change in unrealized appreciation/depreciation on investments and foreign currency translations	(6,637,474)

NET INCREASE (DECREASE) IN NET ASSETS RESULTING FROM OPERATIONS	(6,787,324)

DISTRIBUTIONS TO COMMON SHARES:	
Net investment income	--
Net realized short-term gain on investments and foreign currency transactions	--

TOTAL DISTRIBUTIONS TO COMMON SHARES	--

FUND SHARE TRANSACTIONS:	
Net increase in net assets from common shares issued in offering	--

NET INCREASE IN NET ASSETS FROM FUND SHARE TRANSACTIONS	--

NET INCREASE (DECREASE) IN NET ASSETS	(6,787,324)
NET ASSETS:	
Beginning of period	68,069,259

End of period (including undistributed net investment income of \$0 and \$96,466, respectively)	\$ 61,281,935
	=====

- (a) The Gabelli Healthcare & Wellness (Rx) Trust commenced investment operations on June 28, 2007.

See accompanying notes to financial statements.

6

THE GABELLI HEALTHCARE & WELLNESS (RX) TRUST
FINANCIAL HIGHLIGHTS

Edgar Filing: Gabelli Healthcare & WellnessRx Trust - Form N-CSRS

SELECTED DATA FOR A COMMON SHARE OF BENEFICIAL INTEREST OUTSTANDING
THROUGHOUT EACH PERIOD:

SIX MONTHS END
JUNE 30, 2007
(UNAUDITED)

OPERATING PERFORMANCE:

Net asset value, beginning of period	\$	8.0
Net investment income (loss)		(0.0)
Net realized and unrealized gain (loss) on investments and foreign currency transactions		(0.7)
Total from investment operations		(0.8)

DISTRIBUTIONS TO COMMON SHAREHOLDERS:

Net investment income		-
Net realized short-term gain on investments and foreign currency transactions		-
Total distributions to common shareholders		-

NET ASSET VALUE, END OF PERIOD	\$	7.2
Net asset value total return +		(9.9)
Market value, end of period	\$	6.2
Total investment return++		(12.4)

RATIOS TO AVERAGE NET ASSETS AND SUPPLEMENTAL DATA:

Net assets end of period (in 000's)	\$	61,28
Ratio of net investment income (loss) to average net assets		(1.5)
Ratio of operating expenses to average net assets		2.1
Portfolio turnover rate		64.

+ Based on net asset value per share at commencement of operations of \$8.00 per share, adjusted for reinvestment of distributions at the net asset value per share on the ex-dividend dates. Total returns for periods of less than one year are not annualized.

++ Based on market value per share at initial public offering of \$8.00 per share, adjusted for reinvestment of distributions at prices obtained under the Fund's dividend reinvestment plan. Total returns for periods of less than one year are not annualized.

+++ Effective in 2008, a change in accounting policy was adopted with regard to the calculation of the portfolio turnover rate. Had this policy been adopted retroactively, the portfolio turnover rate for the period ended December 31, 2007 would have been 60.6%.

(a) Annualized.

(b) The Gabelli Healthcare & Wellness (Rx) Trust commenced investment operations on June 28, 2007.

See accompanying notes to financial statements.

THE GABELLI HEALTHCARE & WELLNESS (RX) TRUST
NOTES TO FINANCIAL STATEMENTS (UNAUDITED)

1. ORGANIZATION. The Gabelli Healthcare & Wellness (Rx) Trust (the "Fund") is a non-diversified closed-end management investment company organized as a Delaware statutory trust on February 20, 2007 and registered under the Investment Company Act of 1940 as amended (the "1940 Act"), whose objective is long-term growth of capital. Investment operations commenced on June 28, 2007. The Fund had no operations prior to June 28, 2007, other than the sale of 12,500 common shares for \$100,000 to The Gabelli Equity Trust Inc. (the "Equity Trust"). On June 28, 2007, the Equity Trust contributed \$67,695,672 in cash in exchange for shares of the Fund, and on the same date distributed such shares to the Equity Trust holders of record as of June 21, 2007 at the rate of one share of the Fund for every twenty shares of the Equity Trust common stock.

Under normal market conditions, the Fund will invest at least 80% of its assets in equity securities and income producing securities of domestic and foreign companies in the healthcare and wellness industries.

2. SIGNIFICANT ACCOUNTING POLICIES. The preparation of financial statements in accordance with United States ("U.S.") generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts and disclosures in the financial statements. Actual results could differ from those estimates. The following is a summary of significant accounting policies followed by the Fund in the preparation of its financial statements.

Security Valuation. Portfolio securities listed or traded on a nationally recognized securities exchange or traded in the U.S. over-the-counter market for which market quotations are readily available are valued at the last quoted sale price or a market's official closing price as of the close of business on the day the securities are being valued. If there were no sales that day, the security is valued at the average of the closing bid and asked prices or, if there were no asked prices quoted on that day, then the security is valued at the closing bid price on that day. If no bid or asked prices are quoted on such day, the security is valued at the most recently available price or, if the Board of Trustees (the "Board") so determines, by such other method as the Board shall determine in good faith to reflect its fair market value. Portfolio securities traded on more than one national securities exchange or market are valued according to the broadest and most representative market, as determined by Gabelli Funds, LLC (the "Adviser").

Portfolio securities primarily traded on a foreign market are generally valued at the preceding closing values of such securities on the relevant market, but may be fair valued pursuant to procedures established by the Board if market conditions change significantly after the close of the foreign market but prior to the close of business on the day the securities are being valued. Debt instruments with remaining maturities of 60 days or less that are not credit impaired are valued at amortized cost, unless the Board determines such amount does not reflect the securities' fair value, in which case these securities will be fair valued as determined by the Board. Debt instruments having a maturity greater than 60 days for which market quotations are readily available are valued at the average of the latest bid and asked prices. If there were no asked prices quoted on such day, the security is valued using the closing bid price. Futures contracts are valued at the closing settlement price of the exchange or board of trade on which the applicable contract is traded.

Securities and assets for which market quotations are not readily available are fair valued as determined by the Board. Fair valuation methodologies and procedures may include, but are not limited to: analysis and

Edgar Filing: Gabelli Healthcare & WellnessRx Trust - Form N-CSRS

review of available financial and non-financial information about the company; comparisons to the valuation and changes in valuation of similar securities, including a comparison of foreign securities to the equivalent U.S. dollar value ADR securities at the close of the U.S. exchange; and evaluation of any other information that could be indicative of the value of the security.

8

THE GABELLI HEALTHCARE & WELLNESS (RX) TRUST NOTES TO FINANCIAL STATEMENTS (CONTINUED) (UNAUDITED)

On January 1, 2008, the Fund adopted Statement of Financial Accounting Standard No. 157, "Fair Value Measurements" ("SFAS 157") that clarifies the definition of fair value for financial reporting, establishes a framework for measuring fair value, and requires additional disclosures about the use of fair value measurements. The three levels of the fair value hierarchy under SFAS 157 are described below:

- Level 1 - quoted prices in active markets for identical securities;
- Level 2 - other significant observable inputs (including quoted prices for similar securities, interest rates, prepayment speeds, credit risk, etc.); and
- Level 3 - significant unobservable inputs (including the Fund's determinations as to the fair value of investments).

The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities. The summary of inputs used to value the Fund's net assets as of June 30, 2008 is as follows:

VALUATION INPUTS	INVESTMENTS IN SECURITIES (MARKET VALUE)
Level 1 - Quoted Prices	\$ 52,310,788
Level 2 - Other Significant Observable Inputs	9,806,322
TOTAL	\$ 62,117,110

In March 2008, The Financial Accounting Standards Board (The "FASB") issued Statement of Financial Accounting Standard No. 161, "Disclosures about Derivative Instruments and Hedging Activities" ("SFAS 161") that is effective for fiscal years beginning after November 15, 2008. SFAS 161 is intended to improve financial reporting for derivative instruments by requiring enhanced disclosure that enables investors to understand how and why an entity uses derivatives, how derivatives are accounted for, and how derivative instruments affect an entity's results of operations and financial position. Management is currently evaluating the implications of SFAS 161 on the Fund's financial statement disclosures.

Repurchase Agreements. The Fund may enter into repurchase agreements with primary government securities dealers recognized by the Federal Reserve Board, with member banks of the Federal Reserve System, or with other brokers or dealers that meet credit guidelines established by the Adviser and reviewed by

Edgar Filing: Gabelli Healthcare & WellnessRx Trust - Form N-CSRS

the Board. Under the terms of a typical repurchase agreement, the Fund takes possession of an underlying debt obligation subject to an obligation of the seller to repurchase, and the Fund to resell, the obligation at an agreed-upon price and time, thereby determining the yield during the Fund's holding period. The Fund will always receive and maintain securities as collateral whose market value, including accrued interest, will be at least equal to 102% of the dollar amount invested by the Fund in each agreement. The Fund will make payment for such securities only upon physical delivery or upon evidence of book entry transfer of the collateral to the account of the custodian. To the extent that any repurchase transaction exceeds one business day, the value of the collateral is marked-to-market on a daily basis to maintain the adequacy of the collateral. If the seller defaults and the value of the collateral declines or if bankruptcy proceedings are commenced with respect to the seller of the security, realization of the collateral by the Fund may be delayed or limited. At June 30, 2008, there were no open repurchase agreements.

Investments in other Investment Companies. The Fund may invest, from time to time, in shares of other investment companies (or entities that would be considered investment companies but are excluded from the definition pursuant to certain exceptions under the 1940 Act) (the "Acquired Funds") in accordance with the 1940 Act and related rules. As a shareholder in the Fund, you would bear the pro rata portion of the periodic expenses of the Acquired Funds in addition to the Fund's expenses. For the six months ended June 30, 2008, the Fund did not hold any investments in Acquired Funds.

9

THE GABELLI HEALTHCARE & WELLNESS (RX) TRUST NOTES TO FINANCIAL STATEMENTS (CONTINUED) (UNAUDITED)

Options. The Fund may purchase or write call or put options on securities or indices. As a writer of put options, the Fund receives a premium at the outset and then bears the risk of unfavorable changes in the price of the financial instrument underlying the option. The Fund would incur a loss if the price of the underlying financial instrument decreases between the date the option is written and the date on which the option is terminated. The Fund would realize a gain, to the extent of the premium, if the price of the financial instrument increases between those dates. If a call option is exercised, the premium is added to the proceeds from the sale of the underlying security in determining whether there has been a realized gain or loss. If a put option is exercised, the premium reduces the cost basis of the security.

As a purchaser of put options, the Fund pays a premium for the right to sell to the seller of the put option the underlying security at a specified price. The seller of the put has the obligation to purchase the underlying security upon exercise at the exercise price. If the price of the underlying security declines, the Fund would realize a gain upon sale or exercise. If the price of the underlying security increases or stays the same, the Fund would realize a loss upon sale or at the expiration date, but only to the extent of the premium paid.

In the case of call options, these exercise prices are referred to as "in-the-money", "at-the-money", and "out-of-the-money", respectively. The Fund may write (a) in-the-money call options when the Adviser expects that the price of the underlying security will remain stable or decline during the option period, (b) at-the-money call options when the Adviser expects that the price of the underlying security will remain stable, decline or advance moderately during the option period, and (c) out-of-the-money call options when the Adviser expects that the premiums received from writing the call option will be greater than the appreciation in the price of the underlying security above the exercise price. By writing a call option, the Fund limits its opportunity to profit from

Edgar Filing: Gabelli Healthcare & WellnessRx Trust - Form N-CSRS

any increase in the market value of the underlying security above the exercise price of the option. Out-of-the-money, at-the-money, and in-the-money put options (the reverse of call options as to the relation of exercise price to market price) may be utilized in the same market environments that such call options are used in equivalent transactions. At June 30, 2008, the Fund had no investments in options.

Futures Contracts. The Fund may engage in futures contracts for the purpose of hedging against changes in the value of its portfolio securities and in the value of securities it intends to purchase. Upon entering into a futures contract, the Fund is required to deposit with the broker an amount of cash or cash equivalents equal to a certain percentage of the contract amount. This is known as the "initial margin." Subsequent payments ("variation margin") are made or received by the Fund each day, depending on the daily fluctuations in the value of the contract, which are included in unrealized appreciation/depreciation on investments and futures contracts. The Fund recognizes a realized gain or loss when the contract is closed.

There are several risks in connection with the use of futures contracts as a hedging instrument. The change in value of futures contracts primarily corresponds with the value of their underlying instruments, which may not correlate with the change in value of the hedged investments. In addition, there is the risk that the Fund may not be able to enter into a closing transaction because of an illiquid secondary market. At June 30, 2008 there were no open futures contracts.

Forward Foreign Exchange Contracts. The Fund may engage in forward foreign exchange contracts for hedging a specific transaction with respect to either the currency in which the transaction is denominated or another currency as deemed appropriate by the Adviser. Forward foreign exchange contracts are valued at the forward rate and are marked-to-market daily. The change in market value is included in unrealized appreciation/depreciation on investments and foreign currency translations. When the contract is closed, the Fund records a realized gain or loss equal to the difference between the value of the contract at the time it was opened and the value at the time it was closed.

10

THE GABELLI HEALTHCARE & WELLNESS (RX) TRUST NOTES TO FINANCIAL STATEMENTS (CONTINUED) (UNAUDITED)

The use of forward foreign exchange contracts does not eliminate fluctuations in the underlying prices of the Fund's portfolio securities, but it does establish a rate of exchange that can be achieved in the future. Although forward foreign exchange contracts limit the risk of loss due to a decline in the value of the hedged currency, they also limit any potential gain that might result should the value of the currency increase. In addition, the Fund could be exposed to risks if the counterparties to the contracts are unable to meet the terms of their contracts. At June 30, 2008, there were no open forward foreign exchange contracts in the Fund.

Foreign Currency Translations. The books and records of the Fund are maintained in U.S. dollars. Foreign currencies, investments, and other assets and liabilities are translated into U.S. dollars at the current exchange rates. Purchases and sales of investment securities, income, and expenses are translated at the exchange rate prevailing on the respective dates of such transactions. Unrealized gains and losses that result from changes in foreign exchange rates and/or changes in market prices of securities have been included in unrealized appreciation/depreciation on investments and foreign currency translations. Net realized foreign currency gains and losses resulting from changes in exchange rates include foreign currency gains and losses between

Edgar Filing: Gabelli Healthcare & WellnessRx Trust - Form N-CSRS

trade date and settlement date on investment securities transactions, foreign currency transactions, and the difference between the amounts of interest and dividends recorded on the books of the Fund and the amounts actually received. The portion of foreign currency gains and losses related to fluctuation in exchange rates between the initial trade date and subsequent sale trade date is included in realized gain/(loss) on investments.

Foreign Securities. The Fund may directly purchase securities of foreign issuers. Investing in securities of foreign issuers involves special risks not typically associated with investing in securities of U.S. issuers. The risks include possible revaluation of currencies, the ability to repatriate funds, less complete financial information about companies, and possible future adverse political and economic developments. Moreover, securities of many foreign issuers and their markets may be less liquid and their prices more volatile than those of securities of comparable U.S. issuers.

Foreign Taxes. The Fund may be subject to foreign taxes on income, gains on investments, or currency repatriation, a portion of which may be recoverable. The Fund will accrue such taxes and recoveries as applicable, based upon its current interpretation of tax rules and regulations that exist in the markets in which it invests.

Restricted and Illiquid Securities. The Fund may invest without limit in illiquid securities. Illiquid securities include securities the disposition of which is subject to substantial legal or contractual restrictions. The sale of illiquid securities often requires more time and results in higher brokerage charges or dealer discounts and other selling expenses than does the sale of securities eligible for trading on national securities exchanges or in the over-the-counter markets. Restricted securities may sell at a price lower than similar securities that are not subject to restrictions on resale. Securities freely saleable among qualified institutional investors under special rules adopted by the SEC may be treated as liquid if they satisfy liquidity standards established by the Board. The continued liquidity of such securities is not as well assured as that of publicly traded securities, and accordingly the Board will monitor their liquidity.

Concentration Risks. The Fund will invest a significant portion of its assets in companies in the healthcare and wellness industries. As a result, the Fund may be more susceptible to economic, political, and regulatory developments in this particular sector of the market, positive or negative, and may experience increased volatility to the Fund's NAV and a magnified effect in its total return.

Securities Transactions and Investment Income. Securities transactions are accounted for on the trade date with realized gain or loss on investments determined by using the identified cost method. Interest income (including amortization of premium and accretion of discount) is recorded on the accrual basis. Premiums and discounts on debt

11

THE GABELLI HEALTHCARE & WELLNESS (RX) TRUST NOTES TO FINANCIAL STATEMENTS (CONTINUED) (UNAUDITED)

securities are amortized using the effective yield to maturity method. Dividend income is recorded on the ex-dividend date except for certain dividends which are recorded as soon as the Fund is informed of the dividend.

Custodian Fee Credits and Interest Expense. When cash balances are maintained in the custody account, the Fund receives credits which are used to offset custodian fees. The gross expenses paid under the custody arrangement are

Edgar Filing: Gabelli Healthcare & WellnessRx Trust - Form N-CSRS

included in custodian fees in the Statement of Operations with the corresponding expense offset, if any, shown as "custodian fee credits." When cash balances are overdrawn, the Fund is charged an overdraft fee equal to 110% of the 90 day Treasury Bill rate on outstanding balances. This amount, if any, would be shown as "interest expense" in the Statement of Operations.

Distributions to Shareholders. Distributions to common shareholders are recorded on the ex-dividend date. Distributions to shareholders are based on income and capital gains as determined in accordance with federal income tax regulations, which may differ from income and capital gains as determined under U.S. generally accepted accounting principles. These differences are primarily due to differing treatments of income and gains on various investment securities and foreign currency transactions held by the Fund, timing differences, and differing characterizations of distributions made by the Fund. Distributions from net investment income include net realized gains on foreign currency transactions. These book/tax differences are either temporary or permanent in nature. To the extent these differences are permanent, adjustments are made to the appropriate capital accounts in the period when the differences arise. These reclassifications have no impact on the NAV of the Fund.

The tax character of distributions paid during the period ended December 31, 2007 was as follows:

DISTRIBUTIONS PAID FROM:

Ordinary income	
(inclusive of short-term capital gains)	\$ 423,723

Total distributions paid	\$ 423,723
	=====

Provision for Income Taxes. The Fund intends to continue to qualify as a regulated investment company under Subchapter M of the Internal Revenue Code of 1986, as amended (the "Code"). It is the policy of the Fund to comply with the requirements of the Code applicable to regulated investment companies and to distribute substantially all of its net investment company taxable income and net capital gains. Therefore, no provision for federal income taxes is required.

As of December 31, 2007, the components of accumulated earnings/(losses) on a tax basis were as follows:

Undistributed ordinary income	
(inclusive of short-term capital gains)	\$ 423,078
Net unrealized depreciation on investments and	
foreign currency	(149,491)

Total	\$ 273,587
	=====

The following summarizes the tax cost of investments and the related unrealized appreciation/(depreciation) at June 30, 2008:

	GROSS UNREALIZED APPRECIATION	GROSS UNREALIZED DEPRECIATION	NET UNREALIZED DEPRECIATION
COST			

Edgar Filing: Gabelli Healthcare & WellnessRx Trust - Form N-CSRS

	-----	-----	-----	-----
Investments	\$ 68,996,600	\$ 1,602,884	\$ (8,482,374)	\$ (6,879,490)

12

THE GABELLI HEALTHCARE & WELLNESS (RX) TRUST NOTES TO FINANCIAL STATEMENTS (CONTINUED) (UNAUDITED)

FASB Interpretation No. 48, "Accounting for Uncertainty in Income Taxes, an Interpretation of FASB Statement No. 109" (the "Interpretation") established a minimum threshold for financial statement recognition of the benefit of positions taken in filing tax returns (including whether the Fund is taxable in a particular jurisdiction) and required certain expanded tax disclosures.

For the six months ended June 30, 2008, the Fund did not have any liability for any unrecognized tax benefits. The Fund recognizes interest and penalties, if any, related to unrecognized tax benefits as income tax expenses in the Statement of Operations. The Fund has adopted the Interpretation for all open tax years and it had no impact on the amounts reported in the financial statements.

3. AGREEMENTS AND TRANSACTIONS WITH AFFILIATES. The Fund has entered into an investment advisory agreement (the "Advisory Agreement") with the Adviser which provides that the Fund will pay the Adviser a fee, computed weekly and paid monthly, equal on an annual basis to 1.00% of the value of the Fund's average weekly net assets. In accordance with the Advisory Agreement, the Adviser provides a continuous investment program for the Fund's portfolio and oversees the administration of all aspects of the Fund's business and affairs.

During the six months ended June 30, 2008, the Fund paid brokerage commissions on security trades of \$22,960 to Gabelli & Company, Inc. ("Gabelli & Company"), an affiliate of the Adviser.

The cost of calculating the Fund's NAV per share is a Fund expense pursuant to the Advisory Agreement between the Fund and the Adviser. During the six months ended June 30, 2008, the Fund paid or accrued \$22,500 to the Adviser in connection with the cost of computing the Fund's NAV.

As per the approval of the Board, the Fund compensates officers of the Fund, who are employed by the Fund and are not employed by the Adviser (although the officers may receive incentive based variable compensation from affiliates of the Adviser) and pays its affiliated portion of the cost of the Fund's Chief Compliance Officer. For the six months ended June 30, 2008, the Fund accrued \$35,897, which is included in payroll expenses in the Statement of Operations.

The Fund pays each Trustee who is not considered to be an affiliated person an annual retainer of \$3,000 plus \$1,000 for each Board meeting attended in person and \$500 per telephonic meeting, and they are reimbursed for any out of pocket expenses incurred in attending meetings. In addition, the Audit Committee Chairman receives an annual fee of \$3,000, the Nominating Committee Chairman receives an annual fee of \$2,000, and the Lead Trustee receives an annual fee of \$1,000. Trustees who are directors or employees of the Adviser or an affiliated company receive no compensation or expense reimbursement from the Fund.

4. PORTFOLIO SECURITIES. Purchases and proceeds from the sales of securities for the six months ended June 30, 2008, other than short-term securities and U.S. Government obligations, aggregated \$41,527,493 and \$33,361,545, respectively.

Edgar Filing: Gabelli Healthcare & WellnessRx Trust - Form N-CSRS

5. CAPITAL. The Fund is authorized to issue an unlimited number of shares of beneficial interest (par value \$0.001). The Board has authorized the repurchase of its shares on the open market when the shares are trading on the NYSE at a discount of 10% or more (or such other percentage as the Board may determine from time to time) from the NAV of the shares. During the six months ended June 30, 2008, the Fund did not have any transactions in shares of beneficial interest.

13

THE GABELLI HEALTHCARE & WELLNESS (RX) TRUST
NOTES TO FINANCIAL STATEMENTS (CONTINUED) (UNAUDITED)

Transactions in common shares were as follows:

	PERIOD ENDED DECEMBER 31, 2007 (a)	
	SHARES	AMOUNT
Initial seed capital	12,500	\$ 100,000
Additional shares issued immediately prior to the spin-off from the Equity Trust	8,461,959	67,695,672
Net increase	8,474,459	\$ 67,795,672

(a) The Gabelli Healthcare & Wellness (Rx) Trust commenced investment operations on June 28, 2007.

6. INDEMNIFICATIONS. The Fund enters into contracts that contain a variety of indemnifications. The Fund's maximum exposure under these arrangements is unknown. However, the Fund has not had prior claims or losses pursuant to these contracts and expects the risk of loss to be remote.

7. OTHER MATTERS. On April 24, 2008, the Adviser entered into an administrative settlement with the SEC to resolve the SEC's inquiry regarding prior frequent trading activity in shares of the GAMCO Global Growth Fund (the "Global Growth Fund") by one investor who was banned from the Global Growth Fund in August 2002. In the settlement, the SEC found that the Adviser had violated Section 206(2) of the Investment Advisers Act, Section 17(d) of the 1940 Act and Rule 17d-1 thereunder, and had aided and abetted and caused violations of Section 12(d)(1)(B)(i) of the 1940 Act. Under the terms of the settlement, the Adviser, while neither admitting nor denying the SEC's findings and allegations, agreed, among other things, to pay the previously reserved total of \$16 million (including a \$5 million penalty), of which at least \$11 million will be distributed to shareholders of the Global Growth Fund in accordance with a plan to be developed by an independent distribution consultant and approved by the independent directors of the Global Growth Fund and the staff of the SEC, and to cease and desist from future violations of the above referenced federal securities laws. The settlement will not have a material adverse impact on the Adviser or its ability to fulfill its obligations under the Advisory Agreement. On the same day, the SEC filed a civil action against the Executive Vice President and Chief Operating Officer of the Adviser, alleging violations of certain federal securities laws arising from the same matter. The officer is also an officer of the Global Growth Fund and other funds in the Gabelli/GAMCO

Edgar Filing: Gabelli Healthcare & WellnessRx Trust - Form N-CSRS

fund complex. The officer denies the allegations and is continuing in his positions with the Adviser and the funds. The Adviser currently expects that any resolution of the action against the officer will not have a material adverse impact on the Adviser or its ability to fulfill its obligations under the Advisory Agreement.

On a separate matter, in August 2008, the Adviser made an offer to the staff of the SEC to settle a previously disclosed matter concerning compliance with Section 19(a) and Rule 19a-1 of the 1940 Act by two closed-end funds managed by the Adviser. These provisions require registered investment companies to provide written statements to shareholders when a distribution is made in the nature of a dividend from a source other than net investment income. While the two funds sent annual statements and provided other materials containing this information, the funds did not send the notices required by Rule 19a-1 to shareholders with each distribution in 2002 and 2003. The Adviser believes that the funds have been in compliance with Rule 19a-1 since that time. The Adviser believes that the settlement would have no effect on the funds or any material adverse effect on the Adviser or its ability to manage the funds. This offer of settlement is subject to final agreement regarding the specific language of the SEC's administrative order and other settlement documents and approval by the SEC.

14

TRUSTEES AND OFFICERS
THE GABELLI HEALTHCARE & WELLNESS (RX) TRUST
ONE CORPORATE CENTER, RYE, NY 10580-1422

TRUSTEES

Mario J. Gabelli, CFA

Chairman & Chief Executive Officer,
GAMCO Investors, Inc.

Dr. Thomas E. Bratter

President & Founder, John Dewey Academy

Anthony J. Colavita

Attorney-at-Law,
Anthony J. Colavita, P.C.

James P. Conn

Former Managing Director &
Chief Investment Officer,
Financial Security Assurance Holdings Ltd.

Vincent D. Enright

Former Senior Vice President &
Chief Financial Officer,
KeySpan Corp.

Robert C. Kolodny, MD

Physician, Author, and Lecturer,
General Partner of KBS Partnership

Anthonie C. van Ekris

Chairman, BALMAC International, Inc.

Salvatore J. Zizza

Chairman, Zizza & Co., Ltd.

OFFICERS

Edgar Filing: Gabelli Healthcare & WellnessRx Trust - Form N-CSRS

Bruce N. Alpert
Secretary

Carter W. Austin
Vice President

Peter D. Goldstein
Chief Compliance Officer

Agnes Mullady
President and Treasurer

David I. Schachter
Vice President

Adam E. Tokar
Assistant Vice President & Ombudsman

INVESTMENT ADVISER
Gabelli Funds, LLC
One Corporate Center
Rye, New York 10580-1422

CUSTODIAN
The Bank of New York Mellon

COUNSEL
Willkie Farr & Gallagher LLP

TRANSFER AGENT AND REGISTRAR
Computershare Trust Company, N.A.

STOCK EXCHANGE LISTING

Common

NYSE - Symbol: GRX
Shares Outstanding: 8,474,459

The Net Asset Value per share appears in the Publicly Traded Funds column, under the heading "Specialized Equity Funds," in Monday's The Wall Street Journal. It is also listed in Barron's Mutual Funds/Closed End Funds section under the heading "Specialized Equity Funds."

The Net Asset Value per share may be obtained each day by calling (914) 921-5070 or visiting www.gabelli.com.

For general information about the Gabelli Funds, call 800-GABELLI (800-422-3554), fax us at 914-921-5118, visit Gabelli Funds' Internet homepage at: WWW.GABELLI.COM, or e-mail us at: closedend@gabelli.com

Notice is hereby given in accordance with Section 23(c) of the Investment Company Act of 1940, as amended, that the Fund may, from time to time, purchase its common shares in the open market when the Fund's shares are trading at a discount of 10% or more from the net asset value of the shares.

Edgar Filing: Gabelli Healthcare & WellnessRx Trust - Form N-CSRS

THE GABELLI HEALTHCARE &
WELLNESS (RX) TRUST
ONE CORPORATE CENTER
RYE, NY 10580-1422
(914) 921-5070
WWW.GABELLI.COM

SEMI ANNUAL REPORT
JUNE 30, 2008

GRX Q2/2008

ITEM 2. CODE OF ETHICS.

Not applicable.

ITEM 3. AUDIT COMMITTEE FINANCIAL EXPERT.

Not applicable.

ITEM 4. PRINCIPAL ACCOUNTANT FEES AND SERVICES.

Not applicable.

ITEM 5. AUDIT COMMITTEE OF LISTED REGISTRANTS.

Not applicable.

ITEM 6. INVESTMENTS.

(a) Schedule of Investments in securities of unaffiliated issuers as of the close of the reporting period is included as part of the report to shareholders filed under Item 1 of this form.

(b) Not applicable.

ITEM 7. DISCLOSURE OF PROXY VOTING POLICIES AND PROCEDURES FOR CLOSED-END MANAGEMENT INVESTMENT COMPANIES.

Not applicable.

ITEM 8. PORTFOLIO MANAGERS OF CLOSED-END MANAGEMENT INVESTMENT COMPANIES.

There has been no change, as of the date of this filing, in any of the portfolio managers identified in response to paragraph (a)(1) of this Item in the registrant's most recently filed annual report on Form N-CSR.

Edgar Filing: Gabelli Healthcare & WellnessRx Trust - Form N-CSRS

ITEM 9. PURCHASES OF EQUITY SECURITIES BY CLOSED-END MANAGEMENT INVESTMENT COMPANY AND AFFILIATED PURCHASERS.

REGISTRANT PURCHASES OF EQUITY SECURITIES				
PERIOD	(A) TOTAL NUMBER OF SHARES (OR UNITS) PURCHASED	(B) AVERAGE PRICE PAID PER SHARE (OR UNIT)	(C) TOTAL NUMBER OF SHARES (OR UNITS) PURCHASED AS PART OF PUBLICLY ANNOUNCED PLANS OR PROGRAMS	(D) APPROXIMATE NUMBER OF SHARES BEING PURCHASED
Month #1 01/01/08 through 01/31/08	Common - N/A Preferred - N/A	Common - N/A Preferred - N/A	Common - N/A Preferred - N/A	Common Preferred
Month #2 02/01/08 through 02/28/08	Common - N/A Preferred - N/A	Common - N/A Preferred - N/A	Common - N/A Preferred - N/A	Common Preferred
Month #3 03/01/08 through 03/31/08	Common - N/A Preferred - N/A	Common - N/A Preferred - N/A	Common - N/A Preferred - N/A	Common Preferred
Month #4 04/01/08 through 04/30/08	Common - N/A Preferred - N/A	Common - N/A Preferred - N/A	Common - N/A Preferred - N/A	Common Preferred
Month #5 05/01/08 through 05/31/08	Common - N/A Preferred - N/A	Common - N/A Preferred - N/A	Common - N/A Preferred - N/A	Common Preferred
Month #6 06/01/08 through 06/30/08	Common - N/A Preferred - N/A	Common - N/A Preferred - N/A	Common - N/A Preferred - N/A	Common Preferred
Total	Common - N/A Preferred - N/A	Common - N/A Preferred - N/A	Common - N/A Preferred - N/A	N/A

Footnote columns (c) and (d) of the table, by disclosing the following information in the aggregate for all plans or programs publicly announced:

- a. The date each plan or program was announced - The notice of the potential repurchase of common and preferred shares occurs quarterly in the Fund's quarterly report in accordance with Section 23(c) of the Investment Company Act of 1940, as amended.

Edgar Filing: Gabelli Healthcare & WellnessRx Trust - Form N-CSRS

- b. The dollar amount (or share or unit amount) approved - Any or all common shares outstanding may be repurchased when the Fund's common shares are trading at a discount of 10% or more from the net asset value of the shares. Any or all preferred shares outstanding may be repurchased when the Fund's preferred shares are trading at a discount to the liquidation value of \$25.00.
- c. The expiration date (if any) of each plan or program - The Fund's repurchase plans are ongoing.
- d. Each plan or program that has expired during the period covered by the table - The Fund's repurchase plans are ongoing.
- e. Each plan or program the registrant has determined to terminate prior to expiration, or under which the registrant does not intend to make further purchases. - The Fund's repurchase plans are ongoing.

ITEM 10. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.

There have been no material changes to the procedures by which the shareholders may recommend nominees to the registrant's Board of Trustees, where those changes were implemented after the registrant last provided disclosure in response to the requirements of Item 407(c)(2)(iv) of Regulation S-K (17 CFR 229.407) (as required by Item 22(b)(15) of Schedule 14A (17 CFR 240.14a-101)), or this Item.

ITEM 11. CONTROLS AND PROCEDURES.

- (a) The registrant's principal executive and principal financial officers, or persons performing similar functions, have concluded that the registrant's disclosure controls and procedures (as defined in Rule 30a-3(c) under the Investment Company Act of 1940, as amended (the "1940 Act") (17 CFR 270.30a-3(c))) are effective, as of a date within 90 days of the filing date of the report that includes the disclosure required by this paragraph, based on their evaluation of these controls and procedures required by Rule 30a-3(b) under the 1940 Act (17 CFR 270.30a-3(b)) and Rules 13a-15(b) or 15d-15(b) under the Securities Exchange Act of 1934, as amended (17 CFR 240.13a-15(b) or 240.15d-15(b)).
- (b) There were no changes in the registrant's internal control over financial reporting (as defined in Rule 30a-3(d) under the 1940 Act (17 CFR 270.30a-3(d))) that occurred during the registrant's second fiscal quarter of the period covered by this report that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting.

ITEM 12. EXHIBITS.

- (a) (1) Not applicable.
- (a) (2) Certifications pursuant to Rule 30a-2(a) under the 1940 Act and Section 302 of the Sarbanes-Oxley Act of 2002 are attached hereto.
- (a) (3) Not applicable.

Edgar Filing: Gabelli Healthcare & WellnessRx Trust - Form N-CSRS

(b) Certifications pursuant to Rule 30a-2(b) under the 1940 Act and Section 906 of the Sarbanes-Oxley Act of 2002 are attached hereto.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

(registrant) The Gabelli Healthcare & Wellness(Rx) Trust

By (Signature and Title)* /s/ Agnes Mullady

Agnes Mullady,
Principal Executive Officer and Principal
Financial Officer

Date 9/3/08

Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

By (Signature and Title)* /s/ Agnes Mullady

Agnes Mullady,
Principal Executive Officer and Principal
Financial Officer

Date 9/3/08

* Print the name and title of each signing officer under his or her signature.